-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Woodline Partners LP Sells 75,066 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)
Woodline Partners LP Sells 75,066 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)
Woodline Partners LP decreased its stake in shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) by 15.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 426,170 shares of the company's stock after selling 75,066 shares during the quarter. Woodline Partners LP owned about 1.05% of Acumen Pharmaceuticals worth $2,003,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in ABOS. Fiduciary Group LLC acquired a new position in shares of Acumen Pharmaceuticals during the 1st quarter worth approximately $31,000. California State Teachers Retirement System increased its position in shares of Acumen Pharmaceuticals by 114.9% during the 1st quarter. California State Teachers Retirement System now owns 12,162 shares of the company's stock worth $48,000 after purchasing an additional 6,503 shares during the last quarter. American International Group Inc. lifted its position in shares of Acumen Pharmaceuticals by 163.3% during the 1st quarter. American International Group Inc. now owns 14,047 shares of the company's stock worth $55,000 after buying an additional 8,712 shares during the last quarter. Prelude Capital Management LLC bought a new stake in shares of Acumen Pharmaceuticals during the 1st quarter worth $61,000. Finally, JPMorgan Chase & Co. increased its holdings in Acumen Pharmaceuticals by 149.3% in the 1st quarter. JPMorgan Chase & Co. now owns 18,049 shares of the company's stock worth $71,000 after purchasing an additional 10,809 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company's stock.
Get Acumen Pharmaceuticals alerts:Analyst Ratings Changes
ABOS has been the topic of several recent research reports. Credit Suisse Group cut their price target on Acumen Pharmaceuticals from $17.00 to $16.00 and set an "outperform" rating on the stock in a report on Tuesday, November 15th. BTIG Research raised their target price on Acumen Pharmaceuticals from $15.00 to $22.00 and gave the stock a "buy" rating in a research report on Wednesday, October 5th. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Acumen Pharmaceuticals in a research report on Tuesday, August 16th.
Acumen Pharmaceuticals Stock Performance
Acumen Pharmaceuticals stock opened at $5.53 on Tuesday. The stock's 50 day moving average is $6.99 and its 200 day moving average is $5.85. Acumen Pharmaceuticals, Inc. has a twelve month low of $3.02 and a twelve month high of $10.97.Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.01. On average, research analysts anticipate that Acumen Pharmaceuticals, Inc. will post -1.01 EPS for the current year.
About Acumen Pharmaceuticals
(Get Rating)
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
See Also
- Get a free copy of the StockNews.com research report on Acumen Pharmaceuticals (ABOS)
- Why the Cracker Barrel Selloff Looks Overcooked
- Coinbase Global Stock is a Falling Meat Cleaver
- It's Still Too Soon to Shop for Kohl's Stock
- Three Small-Cap Biotech Stocks to Consider Now
- Two Blue Chip Health Companies The Institutions Are Buying
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Woodline Partners LP decreased its stake in shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) by 15.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 426,170 shares of the company's stock after selling 75,066 shares during the quarter. Woodline Partners LP owned about 1.05% of Acumen Pharmaceuticals worth $2,003,000 at the end of the most recent quarter.
根据最近提交给美国证券交易委员会的13F文件,Woodline Partners LP在第二季度减持了Acumen PharmPharmticals,Inc.(纳斯达克代码:ABOS-GET评级)的股份15.0%。该基金在本季度出售了75,066股后,持有该公司426,170股股票。截至最近一个季度末,Woodline Partners LP拥有Acumen PharmPharmticals约1.05%的股份,价值2,003,000美元。
Several other institutional investors have also recently made changes to their positions in ABOS. Fiduciary Group LLC acquired a new position in shares of Acumen Pharmaceuticals during the 1st quarter worth approximately $31,000. California State Teachers Retirement System increased its position in shares of Acumen Pharmaceuticals by 114.9% during the 1st quarter. California State Teachers Retirement System now owns 12,162 shares of the company's stock worth $48,000 after purchasing an additional 6,503 shares during the last quarter. American International Group Inc. lifted its position in shares of Acumen Pharmaceuticals by 163.3% during the 1st quarter. American International Group Inc. now owns 14,047 shares of the company's stock worth $55,000 after buying an additional 8,712 shares during the last quarter. Prelude Capital Management LLC bought a new stake in shares of Acumen Pharmaceuticals during the 1st quarter worth $61,000. Finally, JPMorgan Chase & Co. increased its holdings in Acumen Pharmaceuticals by 149.3% in the 1st quarter. JPMorgan Chase & Co. now owns 18,049 shares of the company's stock worth $71,000 after purchasing an additional 10,809 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company's stock.
其他几家机构投资者最近也改变了他们在ABOS的头寸。信托集团LLC在第一季度收购了Acumen制药公司的新股票,价值约3.1万美元。加利福尼亚州教师退休系统在第一季度将其在Acumen制药公司的股票头寸增加了114.9%。加利福尼亚州教师退休系统在上个季度购买了6,503股后,现在拥有12,162股该公司股票,价值48,000美元。美国国际集团(American International Group Inc.)在第一季度将其在Acumen PharmPharmticals的持仓提高了163.3%。美国国际集团现在持有14,047股该公司股票,价值55,000美元,在上个季度又购买了8,712股。Prelude Capital Management LLC在第一季度购买了Acumen制药公司价值61,000美元的新股。最后,摩根大通在第一季度增持了Acumen PharmPharmticals的股份149.3%。摩根大通在上个季度又购买了10,809股,目前持有18,049股该公司股票,价值71,000美元。机构投资者和对冲基金持有该公司63.33%的股票。
Analyst Ratings Changes
分析师评级发生变化
ABOS has been the topic of several recent research reports. Credit Suisse Group cut their price target on Acumen Pharmaceuticals from $17.00 to $16.00 and set an "outperform" rating on the stock in a report on Tuesday, November 15th. BTIG Research raised their target price on Acumen Pharmaceuticals from $15.00 to $22.00 and gave the stock a "buy" rating in a research report on Wednesday, October 5th. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Acumen Pharmaceuticals in a research report on Tuesday, August 16th.
ABOS一直是最近几份研究报告的主题。瑞士信贷集团在11月15日周二的一份报告中将Acumen PharmPharmticals的目标价从17.00美元下调至16.00美元,并对该股设定了“跑赢大盘”的评级。BTIG Research在10月5日(周三)的一份研究报告中将Acumen PharmPharmticals的目标价从15.00美元上调至22.00美元,并给予该股“买入”评级。最后,在8月16日星期二的一份研究报告中,HC Wainwright重新发布了买入评级,并对Acumen PharmPharmticals的股票发布了15.00美元的目标价。
Acumen Pharmaceuticals Stock Performance
Acumen制药类股表现
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.01. On average, research analysts anticipate that Acumen Pharmaceuticals, Inc. will post -1.01 EPS for the current year.
Acumen PharmPharmticals(纳斯达克:ABOS-GET评级)最近一次发布季度收益数据是在11月14日(星期一)。该公司公布本季度每股收益(EPS)为0.26美元,比普遍预期的0.27美元高出0.01美元。研究分析师平均预计,Acumen制药公司本年度每股收益将达到1.01欧元。
About Acumen Pharmaceuticals
关于Acumen制药公司
(Get Rating)
(获取评级)
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Acumen制药公司是一家临床阶段的生物制药公司,发现和开发治疗阿尔茨海默病的疗法。该公司专注于开发一种靶向免疫治疗候选药物ACU193,这是一种人源化单抗,正处于I期临床阶段,用于靶向可溶性淀粉样β寡聚体。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Acumen Pharmaceuticals (ABOS)
- Why the Cracker Barrel Selloff Looks Overcooked
- Coinbase Global Stock is a Falling Meat Cleaver
- It's Still Too Soon to Shop for Kohl's Stock
- Three Small-Cap Biotech Stocks to Consider Now
- Two Blue Chip Health Companies The Institutions Are Buying
- 免费获取StockNews.com关于Acumen制药的研究报告(ABOS)
- 为什么饼干桶抛售看起来有点过头了
- Coinbase全球股票是一把正在下跌的割肉刀
- 现在购买科尔的股票还为时过早
- 现在要考虑的三只小盘生物科技股
- 这两家机构正在收购的两家蓝筹健康公司
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Acumen PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Acumen制药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧